Valeant Pharmaceuticals International (VRX)
A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.
Recs
moneycentral rated: 10, navallier rated:A
Recs
Insider trading
Recs
Building a portfolio based on insider cluster buys.
Recs
Both RESTORE trials showed favorable results, and the stock price has risen correspondingly. However, the eventual revenue prospects for retigabine in the crowded anti-epipleptic market are dubious. The company is downplaying taribavirin and appears to be trying to dish it off to some sucker, I mean partner. As far as revenues from marketed products, I can't improve on the CEO's own comments. "The financial results from this quarter continue to highlight the need for decisive change at Valeant," Chief Executive Officer J. Michael Pearson said in a statement. Translation - we suck. The top commerical priority of the company is to improve their marketing in Mexico. Ahem. Hopefully this pick will bring me back to my rightful position as score leader.
Recs
undervalued, EPS 5 Year Growth (%) 199.82
Recs
I was long on this stock until my stop loss triggered. Looks like it may trend down before coming back up. Not willing to bet my $ but I will put it on CAPS.
Recs
near 52 week low

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 7 of 7